UNIQURE BVUNIQURE BVUNIQURE BV

UNIQURE BV

No trades
See on Supercharts
Next report date
Report period
Q1 2024
EPS estimate
−1.19EUR
Revenue estimate
‪5.83 M‬EUR
Market capitalization
‪212.30 M‬EUR
−5.8625EUR
‪−279.48 M‬EUR
‪14.35 M‬EUR
‪43.18 M‬
Beta (1Y)
1.90

About uniQure N.V.

CEO
Matthew C. Kapusta
Headquarters
Amsterdam
Employees (FY)
480
Founded
2012
ISIN
NL0010696654
FIGI
BBG005ZVQ093
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange UNIQURE BV stocks are traded under the ticker UQ1.
UNIQURE BV is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
UQ1 earnings for the last quarter are −1.78 EUR per share, whereas the estimation was −0.81 EUR resulting in a −120.00% surprise. The estimated earnings for the next quarter are −1.32 EUR per share. See more details about UNIQURE BV earnings.
UNIQURE BV revenue for the last quarter amounts to ‪1.33 M‬ EUR despite the estimated figure of ‪27.90 M‬ EUR. In the next quarter revenue is expected to reach ‪5.07 M‬ EUR.
Yes, you can track UNIQURE BV financials in yearly and quarterly reports right on TradingView.
UQ1 net income for the last quarter is ‪−66.33 M‬ EUR, while the quarter before that showed ‪−84.73 M‬ EUR of net income which accounts for 21.72% change. Track more UNIQURE BV financial stats to get the full picture.
No, UQ1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, UQ1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade UNIQURE BV stock right from TradingView charts — choose your broker and connect to your account.
UQ1 reached its all-time high on Jun 24, 2019 with the price of 72.0000 EUR, and its all-time low was 4.0660 EUR and was reached on Apr 25, 2024. View more price dynamics on UQ1 chart.
See other stocks reaching their highest and lowest prices.
As of May 4, 2024, the company has 480.00 employees. See our rating of the largest employees — is UNIQURE BV on this list?
We've gathered analysts' opinions on UNIQURE BV future price: according to them, UQ1 price has a max estimate of 27.70 EUR and a min estimate of 6.46 EUR. Watch UQ1 chart and read a more detailed UNIQURE BV stock forecast: see what analysts think of UNIQURE BV and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. UNIQURE BV EBITDA is ‪−188.52 M‬ EUR, and current EBITDA margin is ‪−1.64 K‬%. See more stats in UNIQURE BV financial statements.